Supernus Pharmaceuticals Inc
SWB:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Supernus Pharmaceuticals Inc (S49) under the Base Case is 59.47 EUR per share.
Compared with the current market price of 37.4 EUR, the stock appears
Undervalued by 37% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Supernus Pharmaceuticals Does
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain.
- Headquarters
- United States of America US
- Employees
- 778
- IPO date
- Dec 28, 2010
Supernus Pharmaceuticals has no economic moat
Supernus Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysisContinue S49 Research
Decided on Supernus Pharmaceuticals? Get an email when S49 reaches the price you’d buy at. Free with an account.
Other Supernus Pharmaceuticals listings
What is the Intrinsic Value of one S49 stock?
The intrinsic value for
Supernus Pharmaceuticals Inc (S49) under the Base Case is 59.47 EUR.
Is S49 stock undervalued or overvalued?
Compared with the current market price of 37.4 EUR, the stock appears Undervalued by 37% .